TrialThe Journal of investigative dermatology2015

Efficacy and safety of omalizumab in patients with chronic idiopathic/spontaneous urticaria who remain symptomatic on H1 antihistamines: a randomized, placebo-controlled study.

Sarbjit S Saini et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.